chemical genomics – biol503 lecture 2 chemical genomics and cancer/cardiovascular diseases

16
Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Post on 19-Dec-2015

216 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Chemical Genomics – Biol503

Lecture 2Chemical Genomics and cancer/cardiovascular

diseases

Page 2: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Anticancer Drug Screen

Page 3: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Traditional Approach: cell growth inhibition

Screen of synthetic and natural product compound libraries for inhibitor of cancer cell-lines

NCI’s cancer cell-lines (free) NCI’s Open Chemical Repository

Collection (140,000 compounds) NCI’s Natural Products Repository

Page 4: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Protein Kinases – cancer and cardiovascular diseases

Page 5: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Cancer Pathways – cellular targets

Source: Prous Integrity

Page 6: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Phosphorylation

Phosphorylation by protein kinases is the most widespread and well-studied signal mechanisms in eukaryotic cells

Kinome: 518 kinases, each phosporylates a distinct set of substrates

Understanding complex network of kinase-based signaling is important for cancer and cardiovascular diseases

Page 7: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Kinase assay – an example

Time resolved FRET

Page 8: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Approved drug: an example

Tykerb (lapatinib ditosylate) is an EGFR and ErbB-2 dual tyrosince kinase inhibitor.

EGFR- epidermal growth factor receptor ErbB-2 (HER2/neu) – Human Epidermal

growth factor Receptor 2 Developed by GlaxoSmithKline Approved by FDA March 2007 for use in

combination with capectabine for patients with advanced, metastatic breast cancer that is HER2 positive.

Page 9: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Protein Tyrosine Phosphatases – cancer and cardiovascular

diseases

Page 10: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Protein tyrosince phosphatases

The PTP superfamily of enzymes functions in a coordinated manner with protein tyrosine kinases to control signal pathways

Regulatory role of protein kinases well established.

But protein phosphatases can no longer viewed as passive housekeeping enzymes in the processes.

Page 11: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Diversity of PTPs

Page 12: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Regulation by dimerization

Page 13: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

Regulation by Ligands

Page 14: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

PTPs and Cancers

Page 15: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

ProFluor Assay

Page 16: Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases

References

Johnson and Hunter, Nature Methods, 2005

N.K. Tonks, Nature Review Mol Cell Biol, 2006